BPC-157 vs Mazdutide (IBI362)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of BPC-157 and Mazdutide (IBI362) (also searched as Mazdutide (IBI362) vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
BPC-157 centers on healing, while Mazdutide (IBI362) leans toward metabolic. On indexed research, BPC-157 is ahead (BPC-157: 6 studies, Human evidence; Mazdutide (IBI362): 1, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •BPC-157 is strongest for healing; Mazdutide (IBI362) for metabolic.
- •Evidence: BPC-157 Human evidence (6 studies) vs Mazdutide (IBI362) Human evidence (1).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Body Protection Compound-157 | Pentadecapeptide
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
BPC-157 vs Mazdutide (IBI362): side-by-side
| Metric | BPC-157 | Mazdutide (IBI362) |
|---|---|---|
| Class | Healing | Weight Loss |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 6 | 1 |
| Research level | Extensively Studied | Extensively Studied |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.3▲ | 0.0 |
| Muscle & body comp | 3.3▲ | 0.0 |
| Metabolic & appetite | 2.3 | 5.0▲ |
| Neuro & mood | 3.0▲ | 0.0 |
| Sleep & circadian | 0.7▲ | 0.0 |
| Inflammation & immune | 4.0▲ | 0.0 |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | BPC-157 | Mazdutide (IBI362) |
|---|---|---|
| Mechanism | Body-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling | GLP-1 / glucagon dual receptor agonist |
| Route | Subcutaneous / oral (research use) | Subcutaneous injection |
| Duration of action | — | Weekly dosing (investigational) |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is BPC-157?
Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.
Full BPC-157 profile, mechanism & studies →What is Mazdutide (IBI362)?
Mazdutide (IBI362) is an investigational dual GLP-1/glucagon receptor agonist studied for weight loss and type 2 diabetes, combining appetite suppression with increased energy expenditure.
Full Mazdutide (IBI362) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | BPC-157 | 4.3/5 effect signal |
| Muscle | BPC-157 | 3.3/5 effect signal |
| Metabolic | Mazdutide (IBI362) | 5.0/5 effect signal |
| Neuro | BPC-157 | 3.0/5 effect signal |
| Sleep | BPC-157 | 0.7/5 effect signal |
| Inflammation | BPC-157 | 4.0/5 effect signal |
| Skin | BPC-157 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack BPC-157 and Mazdutide (IBI362)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
BPC-157 vs Mazdutide (IBI362): side effects
- improved healing28
- flushing14
- vivid dreams11
- nausea3
- anxiety2
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
BPC-157 has 6 approved studies indexed (Human evidence), and Mazdutide (IBI362) has 1 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is BPC-157 or Mazdutide (IBI362) better?
It depends on your goal. BPC-157 is strongest for healing; Mazdutide (IBI362) for metabolic. BPC-157 has more indexed studies (6). See the goal-by-goal breakdown above.
Is BPC-157 or Mazdutide (IBI362) better for weight loss?
Mazdutide (IBI362) shows the stronger metabolic & appetite profile (5.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is BPC-157 or Mazdutide (IBI362) better for muscle?
BPC-157 leads on the muscle & body-composition axis (3.3/5).
Which has more research, BPC-157 or Mazdutide (IBI362)?
BPC-157 has 6 approved studies indexed (Human evidence); Mazdutide (IBI362) has 1 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack BPC-157 and Mazdutide (IBI362)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of BPC-157 vs Mazdutide (IBI362)?
BPC-157: community-reported improved healing, flushing, vivid dreams. Mazdutide (IBI362): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is BPC-157 or Mazdutide (IBI362) FDA-approved?
BPC-157 is a research-use compound and is not FDA-approved. Mazdutide (IBI362) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Mazdutide (IBI362) better than BPC-157?
For metabolic, Mazdutide (IBI362) has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
BPC-157 and Mazdutide (IBI362) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.